Related Experiment Video
Updated: Nov 9, 2025
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-β induced retinal pigmented epithelium
Siddharth Narendran1,2,3, Felipe Pereira1,2,4, Praveen Yerramothu1,2
1Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA, USA.
Abstract:
Nonfibrillar amyloid-β oligomers (AβOs) are a major component of drusen, the sub-retinal pigmented epithelium (RPE) extracellular deposits characteristic of age-related macular degeneration (AMD), a common cause of global blindness. We report that AβOs induce RPE degeneration, a clinical hallmark of geographic atrophy (GA), a vision-threatening late stage of AMD that is currently untreatable. We demonstrate that AβOs induce activation of the NLRP3 inflammasome in the mouse RPE in vivo and that RPE expression of the purinergic ATP receptor P2RX7, an upstream mediator of NLRP3 inflammasome activation, is required for AβO-induced RPE degeneration. Two classes of small molecule inflammasome inhibitors-nucleoside reverse transcriptase inhibitors (NRTIs) and their antiretrovirally inert modified analog Kamuvudines-both inhibit AβOs-induced RPE degeneration. These findings crystallize the importance of P2RX7 and NLRP3 in a disease-relevant model of AMD and identify inflammasome inhibitors as potential treatments for GA.
Insights
Amyloid-β oligomers (AβOs) cause retinal cell degeneration in age-related macular degeneration (AMD). Inhibiting the P2RX7 and NLRP3 inflammasome pathway shows promise for treating geographic atrophy (GA), an advanced form of AMD.
Area of Science:
- Ophthalmology
- Neuroscience
- Immunology
Background:
- Nonfibrillar amyloid-β oligomers (AβOs) are key components of drusen, deposits linked to age-related macular degeneration (AMD).
- AMD, particularly geographic atrophy (GA), is a leading cause of blindness with no current treatments.
- AβOs are implicated in retinal pigment epithelium (RPE) degeneration, a hallmark of GA.
Purpose of the Study:
- To investigate the role of AβOs in RPE degeneration.
- To explore the involvement of the P2RX7 receptor and NLRP3 inflammasome in AβO-induced RPE damage.
- To evaluate the therapeutic potential of inflammasome inhibitors for GA.
Main Methods:
- In vivo studies using a mouse model of RPE degeneration.
- Analysis of AβO-induced inflammasome activation in the RPE.
- Assessment of the requirement for P2RX7 expression in AβO-induced RPE degeneration.
- Testing the efficacy of small molecule inflammasome inhibitors (NRTIs and Kamuvudines).
Main Results:
- AβOs induce RPE degeneration in vivo.
- AβOs activate the NLRP3 inflammasome in the mouse RPE.
- RPE expression of P2RX7 is essential for AβO-induced RPE degeneration.
- Both NRTIs and Kamuvudines effectively inhibit AβO-induced RPE degeneration.
Conclusions:
- P2RX7 and NLRP3 inflammasome activation are critical in a disease-relevant model of AMD.
- Small molecule inflammasome inhibitors demonstrate potential as a novel therapeutic strategy for geographic atrophy (GA).
- Targeting the P2RX7-NLRP3 inflammasome pathway offers a promising avenue for treating vision-threatening AMD stages.
More Related Videos
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
